Search academic texts

Information × Registration Number 0213U002686, 0112U001373 , R & D reports Title To investigate the degree of resistance to replacement therapy based on studies in vivo recovery (IVR) of factors VIII and IX and pharmacokinetic parameters in hemophilia patients with inhibitors popup.stage_title Head Loginsky Volodymyr Eustakhovych, Доктор медичних наук Registration Date 04-02-2013 Organization LVIV RESEARCH INSTITUTE OF BLOOD PATHOLOGY AND TRANSFUSIONAL MEDICINE popup.description2 The object of study was 33 patients with haemophilia A, B and von Willebrand disease, aged 1 to 75 years, men - 29 women - 4, who were in hospital in surgical care to patients with haemophilia at the 5 municipal hospital in Lviv or observed in the dispensary and methodological department of haemophilia and koahulopatiy SI "Institute of Blood Pathology and Transfusion Medicine of Ukraine NAMS" (Lviv). The studies revealed that the pharmacokinetics study is necessary for individual selection of the optimal therapeutic dose, frequency of administration for short-term or long-term treatment depending on the severity of bleeding from the rational use of drugs and cheaper treatment. Investigation of the recovery period imposed factor VIII (IX) is accessible and highly informative test for the early detection of resistance to replacement therapy and individual response to the drug and can be recommended as a screening test for the diagnosis of inhibitor hemophilia A and B. The index recovery (s) may be recommended for calculating individual dose of the concentrates of factor VIII and IX. We revealed that the pharmacokinetic parameters, including area under the curve (AUS), clearance (CL), half-life (T1/2) factors VIII and IX are dependent, to a greater extent on the individual patient, such as the type of hemophilia, severity, age of the patient, and patients with hemophilia A - the blood group, and to a lesser extent on the type of drug blood coagulation factor VIII (IX). In patients with von Willebrand disease pharmacokinetic parameters depend on the age, type of disease and the type of concentrate. Based on the study of pharmacokinetic parameters of von Willebrand's disease detected secondary character of deficiency of factor VIII, which requires the treatment of bleeding in these patients, especially during surgery, used drugs that contain high amount of von Willebrand factor. Aim: Based on research coagulation parameters in vitro and in vivo to develop methods of predicting the severity of hemorrhagic manifestations and determine efficacy concentrates factor VIII, recombinant activated factor VII, coagulation factors II, VII, IX, X, and their combination in patients with hemophilia A with inhibitor. Clinical and laboratory studies included clinical examination, coagulation, hematology, biochemical research. Used Micros 60 hematology analyzer number 81473, biochemical analyzer Point +180, SR 1907.1674, water bath Product Description popup.authors Дзісь Р.П. Красівська В.В. Стасишин О.В. Тушницький О.М. popup.nrat_date 2020-04-02 Close